Search

Your search keyword '"Latham, Lea"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Latham, Lea" Remove constraint Author: "Latham, Lea"
28 results on '"Latham, Lea"'

Search Results

1. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

2. Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11

3. Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

4. Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy

5. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

6. Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

7. Correction to:An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids (Genetics in Medicine, (2021), 23, 4, (740-750), 10.1038/s41436-020-01027-3)

8. An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids

9. Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science

11. Correction: Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations

12. Variants in PRKAR1Bcause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

13. Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases

14. An autosomal dominant neurological disorder caused by de novo variants in FAR1resulting in uncontrolled synthesis of ether lipids

15. Looking beyond the exome: a phenotype-first approach to molecular diagnostic resolution in rare and undiagnosed diseases

16. Clinical outcomes and brain metabolites in patients with late onset Tay-Sachs and Sandhoff disease

17. Safety, pharmacokinetics and sialic acid production after oral administration of N -acetylmannosamine (ManNAc) to subjects with GNE myopathy

18. MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome

19. A Recurrent De Novo Variant in NACC1 Causes a Syndrome Characterized by Infantile Epilepsy, Cataracts, and Profound Developmental Delay

20. The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease

21. A Syndromic Neurodevelopmental Disorder Caused by De Novo Variants in EBF3

22. De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical Phenotype

25. Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

26. Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

27. 978: A Phase II Trial of Docetaxel, Thalidomide and Estramustine in Metastatic Androgen-Independent Prostate Cancer

28. Correction to: An autosomal dominant neurological disorder caused by de novo variants in FAR1resulting in uncontrolled synthesis of ether lipids

Catalog

Books, media, physical & digital resources